{"schema_version":"secwatch.filing_event.v1","accession":"0000875045-25-000040","form_type":"8-K","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.427129+00:00","generated_at":"2026-05-17T04:02:17.752505+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Biogen expects ~$2M pre-tax IPR&D charge for Q3, impact of ($0.01)/share","bullets":["Preliminary estimate: acquired IPR&D, upfront & milestone expense of ~$2M pre-tax.","Estimated impact of ($0.01) per diluted share on both GAAP and non-GAAP EPS.","Q3 2025 results not yet finalized; subject to closing procedures and could differ."],"urls":{"canonical":"https://secwatch.observer/filing/0000875045-25-000040","json":"https://secwatch.observer/filing/0000875045-25-000040.json","markdown":"https://secwatch.observer/filing/0000875045-25-000040.md","text":"https://secwatch.observer/filing/0000875045-25-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000087504525000040/0000875045-25-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000087504525000040/biib-20251014.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:02:17.752505+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}